NEW YORK – The Translational Genomics Research Institute (TGen) said Wednesday that it has partnered with the Soteria Precision Medicine Foundation on cancer testing for members of the US military's special operations forces.
Under the terms of the deal, Soteria will provide cancer patients among the SOF and their care teams access to multiomic diagnostic testing and data analytics. They will share de-identified clinical reports with TGen for interpretation and summary analysis. TGen scientists will also conduct sequencing studies to better understand the molecular features and potential drivers of these cancers. The program will initially focus on patients with solid tumors.
"The initiative aims to improve service member patient navigation and document the efficacy of integrating precision medicine navigation," the partners said in a statement. Financial and other terms of the deal were not disclosed.
Phoenix-based TGen is a part of the City of Hope. In 2022, TGen joined a National Cancer Institute-funded effort to advance cancer genomics for Native Americans in the Southwest. Soteria is based in San Diego.